MODIFICATION of the blood-clotting mechanisms as an adjunct to, or a substitute for, surgery in intracranial aneurysms has interested several workers (Uihlein et al., 1966; Gibbs & O'Gorman, 1967; Mullan & Dawley, 1968; Uttley & Buckell, 1968; Mullan, 1969, personal communication The development of amino-methyl cyclohexane carboxylic acid (AMCA, tranexamic acid), more powerful than EACA both in vitro (Maki & Beller, 1966) and in vivo (Dubber, McNicol & Douglas, 1965) in inhibiting fibrinolysis, prompted the following clinical trial at the South-East Metropolitan Regional Neurosurgical Centre.
Patients and methods
Between March, 1968, and December, 1969 , forty-seven patients with angiographically proved aneurysms were treated conservatively or with nondefinitive surgery (closure of a carotid or anterior cerebral artery). Of these, twenty-five were given AMCA, usually after arterial closure had to be withdrawn because it was not tolerated; the danger of recurrent haemorrhage being then regarded as approaching that of a patient treated by bed rest only. The progress of the patients in the test grouptwenty-five patients having AMCA, and the control group-twenty-two patients not taking it, is compared in Table 1 . Evaluation was limited to the first 2 months after the initial ictus because this is the period in which fibrinolysis is particularly relevant to the fate of the thrombus sealing a rupture in an aneurysmal sac.
In the oral dosages given-1 g thrice daily-no side effects at all were observed.
Five patients in the control group and three patients in the test group had multiple aneurysms.
The table shows a significant difference in both the rate of recurrent haemorrhage and the survivalrate in the two groups.
Conclusion
Evidence that inhibition of fibrinolysis helps to prevent recurrent haemorrhage from intracranial aneurysms. is accumulating. Though the present series is necessarily small because AMCA is not yet marketed in the United Kingdom and supplies are limited, an extended trial of its use appears justified.
